NEW YORK (GenomeWeb News) — Biomarker validation company Axela Biosensors has nonexclusively licensed Beckman Coulter’s Universal Linker Capture technology, the companies said today.
Axela plans to use the technology in conjunction with its dotLab sensors to allow users to define their own biomarker panels and to use either the Axela library of pre-conjugated antibodies or their own reagents with universal linkers.
Axela CEO Rocky Ganske added that using the technologies will “allow users to tag their own antibodies or draw from a library of existing markers to build combined assays with micromolar to picomolar sensitivity requirements."
Financial terms of the deal were not released.